NEWS - Xenikos - Resetting the immune system

18 december 2019

Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial

3 december 2019

Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting

2 december 2019

Xenikos appoints Stanley Musial as Chief Financial Officer and Chief Business Officer

14 oktober 2019

Xenikos receives FDA Fast Track designation for T-Guard® for treating steroid-refractory acute graft-versus-host disease

11 juni 2019

Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard® for treating steroid-refractory acute GVHD

20 december 2018

Xenikos partners with the BMT CTN to conduct a U.S.-based Phase 3 trial to test T-Guard® in aGVHD

16 november 2018

Final results from T-Guard® Phase 1/2 trial in steroid-resistant aGVHD published in journal BBMT

14 mei 2018

Dutch Company Xenikos Secures USD 30 Million in Series B Financing

11 december 2017

Data from phase 1/2 trial with T‑Guard® presented at ASH Annual Meeting

//]]>